Related Experiment Video
Updated: Feb 2, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular
Sarah Rouhana1, Charlotte Farah2, Jerome Roy2
1PhyMedExp, Université de Montpellier, INSERM, CNRS, France; Université Saint Joseph, Beyrouth, Lebanon.
Insights
Heart failure with preserved ejection fraction (HFpEF) involves altered cardiac calcium handling. HFpEF hearts show stronger contractions and larger calcium transients due to sarcoplasmic reticulum calcium leak and impaired sodium-calcium exchanger function.
Area of Science:
- Cardiology
- Molecular Biology
- Physiology
Background:
- Heart failure with preserved ejection fraction (HFpEF) presents significant morbidity and mortality.
- Limited understanding of HFpEF pathology hinders therapeutic development.
Purpose of the Study:
- Investigate the cellular phenotype and calcium (Ca2+) handling in a rat model of HFpEF.
- Characterize cardiac remodeling and Ca2+ cycling dynamics in HFpEF.
Main Methods:
- Induction of HFpEF in male Wistar rats via abdominal aortic banding.
- Analysis of cardiac structure, function, and Ca2+ handling proteins.
Main Results:
- HFpEF rats exhibited preserved ejection fraction, hypertension, lung congestion, and cardiac hypertrophy.
- Enhanced left ventricular cell contraction and larger Ca2+ transients were observed.
- Modified Ca2+ cycling involved RyR2-mediated Ca2+ leak and impaired NCX function, increasing diastolic Ca2+.
- Augmented PLN/SERCA2a ratio and increased PLN phosphorylation at PLN-Thr17 indicated complex Ca2+ handling adaptations.
Conclusions:
- Cardiac remodeling in HFpEF differs from heart failure with reduced ejection fraction.
- HFpEF involves intricate, interdependent adaptations in systolic and diastolic Ca2+ handling.
- Understanding these Ca2+ cycling mechanisms is crucial for developing HFpEF therapies.
Abstract:
Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome associated with high morbidity and mortality. Therapeutic options are limited due to a lack of knowledge of the pathology and its evolution. We investigated the cellular phenotype and Ca2+ handling in hearts recapitulating HFpEF criteria. HFpEF was induced in a portion of male Wistar rats four weeks after abdominal aortic banding. These animals had nearly normal ejection fraction and presented elevated blood pressure, lung congestion, concentric hypertrophy, increased LV mass, wall stiffness, impaired active relaxation and passive filling of the left ventricle, enlarged left atrium, and cardiomyocyte hypertrophy. Left ventricular cell contraction was stronger and the Ca2+ transient larger. Ca2+ cycling was modified with a RyR2 mediated Ca2+ leak from the sarcoplasmic reticulum and impaired Ca2+ extrusion through the Sodium/Calcium exchanger (NCX), which promoted an increase in diastolic Ca2+. The Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA2a) and NCX protein levels were unchanged. The phospholamban (PLN) to SERCA2a ratio was augmented in favor of an inhibitory effect on the SERCA2a activity. Conversely, PLN phosphorylation at the calmodulin-dependent kinase II (CaMKII)-specific site (PLN-Thr17), which promotes SERCA2A activity, was increased as well, suggesting an adaptive compensation of Ca2+ cycling. Altogether our findings show that cardiac remodeling in hearts with a HFpEF status differs from that known for heart failure with reduced ejection fraction. These data also underscore the interdependence between systolic and diastolic "adaptations" of Ca2+ cycling with complex compensative interactions between Ca2+ handling partner and regulatory proteins.
Related Concept Videos
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics

